Advertisement

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

Cost of Care
Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Peter Clark, MA, MD, FRCP: A Payer Perspective

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Advertisement

Advertisement




Mar
06
Today In Oncology
FDA Approves Teclistamab and Daratumumab For Relapsed or Refractory Multiple Myeloma
Medical Societies and More Respond to HHS RFI on AI Use in Clinical Care
Accuracy of Molecular Inference–Based AI Model for CNS Tumor Diagnosis
Activity Observed with Novel KRAS Inhibitor in Pancreatic Cancer
Short-Term Vaginal Estrogen Therapy Does Not Increase Risks of Endometrial Cancer Recurrence
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo